Summary
The FDA will hold meetings to discuss lifting restrictions on 12 peptides that were banned in 2023 due to safety concerns. The meetings come after pressure from Health Secretary Robert F. Kennedy Jr., who supports these unproven peptide drugs.
Key Facts
- The FDA banned 12 peptides in 2023 because they posed safety risks.
- The agency scheduled advisory meetings in July 2024 and February 2027 to reconsider these restrictions.
- Robert F. Kennedy Jr., who supports these peptides, has no medical or scientific background.
- Kennedy has publicly promoted the use of these unproven peptides and criticized the FDA's ban.
- The advisory panel reviewing the peptides currently has many vacancies and only a few voting members.
- There are concerns that Kennedy may influence this panel to ease restrictions without strong scientific evidence.
- Peptide drugs are short chains of amino acids; some FDA-approved ones are used for diseases like diabetes.
- The banned peptides are often sold online without proof they work or are safe.
